Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

Safusidenib (AB-218, DS-1001)

J201 Phase 2

Nuvation Bio · Phase 2 · Active, not recruiting · Enrollment 25

NCT04458272

Catalyst Primary completion. 03.10.2023. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy
Safusidenib 250 mg BIDIDH1-mutant grade 2 glioma, Japan (n = 27 per company; registry n = 25)250 mgSingle armn/rconfirmed objective response rate: 51.9%, median follow-up 38.8 months36-month PFS rate: 79.1%, median follow-up 38.8 months